Article Sidebar
Published:
Apr 26, 2023Article Details
Copyright of published material remains in the Authors’ name. This allows authors to use their work for their own non-commercial purposes without seeking permission from the Publisher, subject to properly acknowledging the Journal as the original place of publication.
Authors are free to copy, print and distribute their articles, in full or in part, for teaching activities, and to deposit or include their work in their own personal or institutional database or on-line website. Authors are requested to inform the Journal/Publishers of their desire/intention to include their work in a thesis or dissertation or to republish their work in any derivative form (but not for commercial use).
Material submitted for publication in the SAJCC is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement.
Main Article Content
A review of the use of inhaled nitric oxide in the PICU at Red Cross War Memorial Children’s Hospital, 2011-2015: A retrospective cohort study
Abstract
Background: Inhaled nitric oxide (iNO) functions as a selective pulmonary vasodilator. It is an expensive treatment that is often employed as rescue
therapy for refractory hypoxaemia in acute respiratory distress syndrome (ARDS) and pulmonary hypertension (PHT) following cardiac surgery.
Objectives: To describe the use of iNO and the cost of treatment in our paediatric intensive care unit (PICU).
Methods: A retrospective descriptive study of all patients treated with iNO in the PICU at Red Cross War Memorial Children’s Hospital (RCWMCH) from 2011 - 2015.
Results: We treated 140 patients with iNO, 82 for PHT following cardiac surgery, 53 for ARDS and 5 for persistent pulmonary hypertension of the newborn (PPHN). A response to treatment was observed in 64% of the cohort as a whole, 80% of those with PPHN, 67% of those with PHT post-cardiac surgery, and 64% of those with ARDS. A longer duration of PICU and hospital admission, and higher in-hospital mortality (53%), was seen in the group with ARDS, in particular those with adenoviral infection (63%), when compared with patients treated for PHT post-cardiac surgery (18%) and for PPHN (20%). The total cost of treatment with iNO was ZAR1 441 376 for the 5-year period studied. There are no protocols guiding the use of iNO in our unit, and it was found that response to treatment was not being objectively measured and documented, and that practice varied between clinicians.
Conclusions: Considering the cost of treatment and lack of evidence showing improved outcomes with iNO therapy, its continued use in our resource- limited setting should be guided by protocol.
